STHLM3 - Prostate Cancer Diagnostic Trial
STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer
Prostate Cancer
DIAGNOSTIC_TEST: STHLM3
Number of biopsies, Recorded directly after biopsy
Number of Gleason Score â‰¥ 7, Recorded directly after biopsy|Number of Gleason Score 6, Recorded directly after biopsy|Number of benign, Recorded directly after biopsy
STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer